Cidara is a clinical stage biotechnology company focused on the development of novel anti-infectives. Our pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical, and CD201, our lead candidate for multi-drug resistant bacteria generated by our Cloudbreak™ immunotherapy discovery platform.

Our Mission

Cidara seeks to save or improve patients’ lives through the development of anti-infectives that transform the standard of care. Our initial portfolio is comprised of proprietary product candidates for the treatment of serious fungal and bacterial infections.

There is an urgent and growing need not only for improved anti-infectives but also for entirely new therapeutic approaches to treat and prevent fungal, bacterial, and viral pathogens, particularly those that are increasingly resistant to available treatments.

CD101 IV

CD101 IV is a novel echinocandin antifungal with potent activity against Candida, Aspergillus and PCP. We are developing CD101 IV for once weekly use. We have completed Phase 1 trials and are currently conducting an international Phase 2 trial in candidemia.

CD101 Topical

We are developing CD101 topical to be the first echinocandin ever available to treat vulvovaginal candidiasis (VVC). CD101 has demonstrated potent fungicidal activity against Candida. We are currently conducting a Phase 2 trial in acute VVC.

Cloudbreak™ / CD201

Cloudbreak is a proprietary immunotherapy discovery platform that has the potential to do for infectious disease what immunotherapy has done for cancer. CD201 is our lead Cloudbreak candidate intended to direct a patient’s immune cells to attack bacterial infections.